The FDA is utilizing generative AI tools like Elsa and Peer AI to aid in drafting clinical and regulatory documents for drug development.

1 report, 1 independent Updated Jun 17

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA

Keep exploring

Part of

ODD announced that it is working with the FDA to reduce regulatory uncertainty for its drug development process. All 2 developments

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.Aug 28

Coverage

Newest first; wire copies grouped

Jun 17yahoo.com